Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
国浩律师（深圳）事务所关于特一药业集团股份有限公司2026年限制性股票激励计划调整及授予事项的法律意见书
Regulatory Filings Classification · 85% confidence The document is a standalone legal opinion letter provided by Grandall Law Firm regarding adjustments and grants under a 2026 restricted stock incentive plan. It does not contain financial statements, earnings metrics, or voting results, nor is it announcing a meeting or management change. It is a compliance/legal document submitted as part of regulatory filings (e.g., to a stock exchange or securities regulator). There is no specific category for lawyer opinions, so the correct fallback is Regulatory Filings (RNS).
2026-05-25 Chinese
关于向公司2026年限制性股票激励计划激励对象首次授予限制性股票的公告
Share Issue/Capital Change Classification · 85% confidence The document is an official announcement by 特一药业 regarding the first grant of restricted stock under its 2026 restricted stock incentive plan. It details the number of shares, price, recipients, and the plan’s terms. This is not a financial report (no full financial statements), earnings release, M&A, or management change; rather it’s an issuance of equity under a share‐based compensation plan. This falls under “Share Issue/Capital Change” (SHA).
2026-05-25 Chinese
2026年限制性股票激励计划首次授予激励对象名单（授予日）
Share Issue/Capital Change Classification · 97% confidence The document is an official announcement by the company’s board detailing the first grant of restricted shares under its 2026 employee stock incentive plan. It specifies allocations of new share issuances to directors, senior management, and employees. This falls under announcements of new share issues/capital changes rather than a broader management or financial report. Therefore, it is classified as a Share Issue/Capital Change (SHA).
2026-05-25 Chinese
关于第六届董事会第九次会议决议的公告
Share Issue/Capital Change Classification · 85% confidence The document is an official announcement of the Board of Directors’ resolutions concerning adjustments to the 2026 restricted stock incentive plan and the first-time grant of restricted shares to employees. It does not involve a change in board membership or management, nor is it an AGM materials or an earnings release. Instead, it details the issuance of 11.163 million new restricted shares and changes to the share incentive plan—i.e., a capital change via share issuance under the company’s equity incentive plan. According to the filing definitions, this falls under Share Issue/Capital Change (Code: SHA).
2026-05-25 Chinese
董事会薪酬与考核委员会关于2026年限制性股票激励计划调整事项及首次授予相关事项的核查意见
Share Issue/Capital Change Classification · 85% confidence The document is a formal disclosure by the company’s Board Remuneration and Assessment Committee regarding adjustments to the 2026 restricted stock incentive plan and the initial grant of the restricted shares. It details the number of shares to be granted, adjustments in participant numbers, reserved shares, grant conditions, and related compliance with laws and stock exchange rules. This is an announcement of a corporate capital change—in particular, the issuance of restricted shares under an equity incentive plan. Therefore, it falls under "Share Issue/Capital Change".
2026-05-25 Chinese
关于调整公司2026年限制性股票激励计划首次授予激励对象名单及授予数量的公告
Share Issue/Capital Change Classification · 82% confidence The document is a formal regulatory announcement by a listed company regarding adjustments to the allocation and quantities of restricted stock under its 2026 equity incentive plan. It is not the text of an annual or interim report, nor an earnings release, call transcript, or proxy solicitation. Rather, it directly pertains to the issuance of shares under a compensation plan and adjustments in share allocation. This aligns with the definition of Share Issue/Capital Change (SHA), which covers announcements about new share issues or other capital changes.
2026-05-25 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.